Antibodies to watch in 2020

mAbs

Volumn 12, Issue 1, 2020, Pages

  Kaplon, Hélène ^a   Muralidharan, Mrinalini ^b   Schneider, Zita ^c   Reichert, Janice M ^b  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b Antibody Society   (United States)

^c Scholar Rock   (United States)

Author keywords

Antibody therapeutics; cancer; European Medicines Agency; Food and Drug Administration; immune mediated disorders; monoclonal antibodies

Indexed keywords

ADAKVEO; ADUCANUMAB; ANIFROLUMAB; ASG22ME; BELANTAMAB MAFODOTIN; BEOVU; BROLUCIZUMAB; CRIZANLIZUMAB; ENFORTUMAB VEDOTIN; EPTINEZUMAB; ETROLIZUMAB; EVINACUMAB; HZN 001; INEBILIZUMAB; ISATUXIMAB; LERONLIMAB; MARGETUXIMAB; MONOCLONAL ANTIBODY; NARSOPLIMAB; OPORTUZUMAB MONATOX; PAMREVLUMAB; POLATUZUMAB VEDOTIN; POLIVY; RISANKIZUMAB; ROMOSOZUMAB; SACITUZUMAB GOVITECAN; SATRALIZUMAB; SPARTALIZUMAB; SUTIMLIMAB; TAFASITAMAB; TANEZUMAB; TEPROTUMUMAB; TRASTUZUMAB DERUXTECAN; UBLITUXIMAB; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BLOOD VESSEL OCCLUSION; CHRONIC LYMPHATIC LEUKEMIA; DIFFUSE LARGE B CELL LYMPHOMA; DIPLOPIA; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; ERYTHRODERMIC PSORIASIS; EXOPHTHALMOS; FOOD AND DRUG ADMINISTRATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; LICENCE; MIGRAINE; MULTIPLE MYELOMA; MYELOOPTIC NEUROPATHY; NONALCOHOLIC STEATOHEPATITIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIPELINE; PROGRESSION FREE SURVIVAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSITIONAL CELL CARCINOMA; WET MACULAR DEGENERATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; EUROPEAN UNION; GOVERNMENT REGULATION; IMMUNOLOGY; MARKETING; NEOPLASM; UNITED STATES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; EUROPEAN UNION; GOVERNMENT REGULATION; HUMANS; MARKETING; NEOPLASMS; UNITED STATES;

EID: 85077143865     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2019.1703531     Document Type: Article

References (106)

1. Kaplon H, Reichert JM., Antibodies to watch in 2019. MAbs. 2019;11(2):219–24. doi:10.1080/19420862.2018.1556465.
2. Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10(2):183–203. doi:10.1080/19420862.2018.1415671.
3. Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9(2):167–81. doi:10.1080/19420862.2016.1269580.
4. Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8(2):197–204. doi:10.1080/19420862.2015.1125583.
5. Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8. doi:10.4161/19420862.2015.988944.
6. Reichert JM. Antibodies to watch in 2014: mid-year update. MAbs. 2014;6(4):799–802. doi:10.4161/mabs.29282.
7. Reichert JM. Antibodies to watch in 2014. MAbs. 2014;6(1):5–14. doi:10.4161/mabs.27333.
8. Reichert JM. Antibodies to watch in 2013: mid-year update. MAbs. 2013;5(4):513–17. doi:10.4161/mabs.24990.
9. Reichert JM. Which are the antibodies to watch in 2013? MAbs. 2013;5(1):1–4. doi:10.4161/mabs.22976.
10. Reichert JM. Which are the antibodies to watch in 2012? MAbs. 2012;4(1):1–3. doi:10.4161/mabs.4.1.18719.
11. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76–99. doi:10.4161/mabs.3.1.13895.
12. Reichert JM. Antibodies to watch in 2010. MAbs. 2010;2(1):84–100. doi:10.4161/mabs.2.1.10677.
13. U.S. Food and Drug Administration. Drug approval package: CABLIVI. [cited 2019 Dec 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761112Orig1s000TOC.cfm
14. European Medicines Agency. Annex I summary of product characteristics. [cited 2019 Dec 5]. Available from: https://www.ema.europa.eu/en/documents/product-information/cablivi-epar-product-information_en.pdf.
15. Amgen, Inc. EVENITY™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture. 2019 Jan 8. press release. [cited 2019 Dec 5]. Available from: https://www.amgen.com/media/news-releases/2019/01/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patients-at-high-risk-of-fracture/.
16. U.S. Food and Drug Administration. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. 2019 Apr 9. press release. [cited 2019 Dec 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture.
17. UCB, Amgen. EVENITY® (romosozumab) receives positive CHMP opinion for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. 2019 Oct 18. press release. [cited 2019 Dec 5]. Available from: https://www.ucb.com/stories-media/Press-Releases/article/EVENITY-romosozumab-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Severe-Osteoporosis-in-Postmenopausal-Women-at-High-Risk-of-Fracture.
18. U.S. Food and Drug Administration. SKYRIZI approval letter. [cited 2019 Dec 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761105s000ltr.pdf.
19. Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–86. doi:10.1016/S0140-6736(19)30952-3.
20. Langley RG, Blauvelt A, Gooderham M, Papp K, Philipp S, Wu JJ, Igarashi A, Geng Z, Wu T, Camez A, et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial. [cited 2019 Dec 5]. Available from: https://server.aad.org/eposters/Submissions/getFile.aspx?id=10093&type=sub.
21. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. doi:10.1016/S0140-6736(18)31713-6.
22. U.S. Food and Drug Administration. Polivy approval letter. [cited 2019 Dec 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761121Orig1s000ltr.pdf.
23. Novartis. Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. 2019 Oct 8. press release. [cited 2019 Dec 5]. Available from: https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.
24. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG,; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019:S0161-6420(18)33018–5. doi:10.1016/j.ophtha.2019.04.017.
25. Novartis. Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD. 2018 Oct 27. press release. [cited 2019 Dec 5]. Available from: https://www.novartis.com/news/media-releases/two-year-data-novartis-brolucizumab-reaffirm-superiority-versus-aflibercept-reducing-retinal-fluid-patients-namd.
26. US Food and Drug Administration. FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease. 2019 Nov 15. press release. [cited 2019 Dec 5]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-patients-painful-complication-sickle-cell-disease.
27. Novartis. FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101). 2019 Jul 16. press release. [cited 2019 Dec 5]. Available from: https://www.novartis.com/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101.
28. Kutlar A, Kanter J, Liles DK, Alvarez OA, Cançado RD, Friedrisch JR, Knight-Madden JM, Bruederle A, Shi M, Zhu Z, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol. 2019;94(1):55–61. doi:10.1002/ajh.25308.
29. BIOCAD. BIOCAD registered the first Russian original therapeutic monoclonal antibody 2019 May 7. press release. [[cited 2019 Dec 5]. Available from: https://biocadglobal.com/post/Russian_original_therapeutic_monoclonal_antibody.
30. Kostareva O, Kolyadenko I, Ulitin A, Ekimova V, Evdokimov S, Garber M, Tishchenko S, Gabdulkhakov A. Fab fragment of VHH-based antibody netakimab: crystal structure and modeling interaction with cytokine IL-17A. Crystals. 2019;9(3):177. doi:10.3390/cryst9030177.
31. Zydus. Zydus to launch novel biologic for rabies, TwinrabTM. [cited 2019 Dec 5]. Available from: https://zyduscadila.com/public/pdf/pressrelease/Zydus%20to%20launch%20novel%20biologic%20for%20rabies_WHO.pdf.
32. U.S. Food and Drug Administration. Monoclonal antibody product development for rabies post-exposure prophylaxis. 2017 Jul 17. https://www.fda.gov/media/107165/download.
33. Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals reports second quarter 2019 financial and operating results. 2019 Aug 6. press release. [cited 2019 Dec 5]. Available from: https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-reports-second-quarter-2019-financial.
34. Horizon Pharma plc. Horizon Pharma plc announces Phase 3 confirmatory trial evaluating teprotumumab (OPTIC) for the treatment of active thyroid eye disease (TED) met primary and all secondary endpoints. 2019 Feb 28. press release. [cited 2019 Dec 5]. Available from: https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-announces-phase-3-confirmatory-trial.
35. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–61. doi: 10.1056/NEJMoa1614949.
36. Horizon Pharma plc. Horizon therapeutics plc announces the FDA has granted priority review of the teprotumumab biologics license application (BLA) for the treatment of active thyroid eye disease (TED). 2019 Sept 9. press release. [cited 2019 Dec 5]. Available from: https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-has-granted-priority.
37. Seattle Genetics, Astellas. Seattle Genetics and Astellas announce submission of biologics license application to FDA for enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer. 2019 Jul 16. press release. [cited 2019 Dec 5]. Available from: http://investor.seattlegenetics.com/news-releases/news-release-details/seattle-genetics-and-astellas-announce-submission-biologics.
38. Petrylak DP, Balar AV, O’Donnell PH, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli J, et al. EV-201: results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. J Clin Oncol. 2019 June 20; 37(18_suppl):4505–4505. doi:10.1200/JCO.2019.37.18_suppl.LBA4505.
39. Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, et al. The mechanism of action of the anti-cd38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–87. doi:10.1158/1078-0432.CCR-18-1597.
40. Sanofi. Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma. 2019 June 2. press release. [cited 2019 Dec 5]. Available from: http://www.news.sanofi.us/press-releases?item=137220.
41. Sanofi. FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma. 2019 Jul 10. press release. [cited 2019 Dec 5]. Available from: https://www.sanofi.com/en/media-room/press-releases/2019/2019-07-10-07-00-00.
42. AstraZeneca and Daiichi Sankyo Company, Limited. Trastuzumab deruxtecan granted FDA priority review for treatment of patients with HER2-positive metastatic breast cancer. 2019 Oct 17. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html.
43. AstraZeneca and Daiichi Sankyo Company, Limited. Pivotal phase II DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in H2 2019. 2019 May 8. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019.html.
44. Daiichi Sankyo Company, Limited. Daiichi Sankyo advances [Fam-] Trastuzumab deruxtecan (DS-8201) in Japan with regulatory submission in HER2 positive metastatic breast cancer. 2019 Sept 9. press release. [cited 2019 Dec 5]. Available from: https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/007047.html.
45. AstraZeneca and Daiichi Sankyo Company, Limited. AstraZeneca announces two lancet oncology publications of phase I dose-expansion results of trastuzumab deruxtecan in HER2-positive metastatic breast and gastric cancer. 2019 Apr 29. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/media-centre/medical-releases/astrazeneca-announces-two-lancet-oncology-publications-of-phase-i-dose-expansion-results-of-trastuzumab-deruxtecan-in-her2-positive-metastatic-breast-and-gastric-cancer.html#!
46. Viela Bio. Viela Bio announces U.S. fda accepts for review inebilizumab biologics license application for neuromyelitis optica spectrum disorder. 2019 Aug 27. press release. [cited 2019 Dec 5]. Available from: https://vielabio.com/bla_accept/.
47. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, et al.; N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019:S0140-6736(19)31817–3. doi:10.1016/S0140-6736(19)31817-3.
48. CytoDyn Inc. CytoDyn reaches historical milestone, submits first of three sections of BLA to FDA for Leronlimab (PRO 140) as a combination therapy for HIV. 2019 Mar 18. press release. [cited 2019 Dec 5]. Available from: https://www.cytodyn.com/investors/news-events/press-releases/detail/321/cytodyn-reaches-historical-milestonesubmits-first-of.
49. CytoDyn Inc. Investor presentation. 2019 Sept 25.https://content.equisolve.net/_cb938b9f9372eed3b2f00594e8a2df74/cytodyn/db/193/2912/pdf/CytoDyn+-+Investor_presentation+-+Sep-25-2019-Final.pdf.
50. CytoDyn Inc. CytoDyn provides update on dose escalating trial with leronlimab for HIV monotherapy for a potential pivotal trial. 2019 Aug 14. press release. [cited 2019 Dec 5]. Available from: https://www.cytodyn.com/newsroom/press-releases/detail/350/cytodyn-provides-update-on-dose-escalating-trial-with.
51. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019 Aug/Sep;11(6):987–95. doi:10.1080/19420862.2019.1632115.
52. Immunomedics, Inc. Immunomedics receives complete response letter from FDA for sacituzumab govitecan biologics license application. 2019 Jan 17. press release. [cited 2019 Dec 5]. Available from: https://www.immunomedics.com/our-company/news-and-events/immunomedics-receives-complete-response-letter-from-fda-for-sacituzumab-govitecan-biologics-license-application/.
53. Immunomedics, Inc. Immunomedics resubmits biologics license application to the FDA for sacituzumab govitecan. 2019 Dec 3. press release. [cited 2019 Dec 5]. Available from: https://www.immunomedics.com/our-company/news-and-events/immunomedics-resubmits-biologics-license-application-to-the-fda-for-sacituzumab-govitecan/.
54. Immunomedics, Inc. Immunomedics and everest medicines announce exclusive license agreement for sacituzumab govitecan in East and Southeast Asia excluding Japan. 2019 Apr 29. press release. [cited 2019 Dec 5]. Available from: https://www.immunomedics.com/our-company/news-and-events/immunomedics-and-everest-medicines-announce-exclusive-license-agreement-for-sacituzumab-govitecan-in-east-and-southeast-asia-excluding-japan/.
55. European Medicines Agency. Applications for new human medicines under evaluation by the committee for medicinal products for human use. 2019 Oct. [cited 2019 Dec 5]. Available from: https://www.ema.europa.eu/en/documents/report/applications-new-human-medicines-under-evaluation-chmp-october-2019_en.pdf.
56. Chugai Pharmaceutical Co., Ltd. chugai receives orphan drug designation for satralizumab in neuromyelitis optica and neuromyelitis optica spectrum disorder from the ministry of health, labour and welfare. 2019 Sept 13. press release. [cited 2019 Dec 5]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20190913140000_646.html..
57. Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, et al. Trial of satralizumab in neuromyelitis optica Spectrum disorder. N Engl J Med. 2019;381(22):2114–24. doi:10.1056/NEJMoa1901747.
58. Chugai Pharmaceutical Co., Ltd. Chugai presents results from second positive global Phase III clinical study of satralizumab in NMOSD at ECTRIMS 2019. 2019 Sept 12. press release. [cited 2019 Dec 5]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20190912140300_638.html..
59. Omeros Corporation. Narsoplimab (OMS721). Omeros corporation streamlines path to biologics license application for OMS721 in HSTC-TMA following meeting with FDA. 2019 Feb 14. press release. [cited 2019 Dec 5]. Available from: https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-streamlines-path-biologics-license.
60. Omeros Corporation. Omeros corporation initiates BLA submission for narsoplimab for the treatment of HSCT-TMA. 2019 Oct 28. press release. [cited 2019 Dec 5]. Available from: https://investor.omeros.com/news-releases/news-release-details/omeros-corporation-initiates-bla-submission-narsoplimab.
61. Rambaldi A, Khaled S, Smith M, Zecca M, Kwong YM, Claes K, Leung N, Whitaker S. Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathies (HCT-TMA). Eur Hematol Assoc Lib. 2018 Jun 15; 215162:PF724. [cited 2019 Dec 5]. Available from: https://library.ehaweb.org/eha/2018/stockholm/215162/alessandro.rambaldi.improved.survival.following.oms721.treatment.of.html
62. Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, Kneba M, Repp R, Humpe A, Gramatzki M, et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia. 2013;27(7):1595–98. doi:10.1038/leu.2012.373.
63. MorphoSys AG. MorphoSys AG reports second quarter 2019 financial results. 2019 Aug 6. press release. [cited 2019 Dec 5]. Available from: https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2019-financial-results.
64. MorphoSys AG. MorphoSys AG: primary endpoint met in real-world data study demonstrating clinical superiority of the combination of tafasitamab and lenalidomide compared to lenalidomide alone. 2019 Oct 29. press release. [cited 2019 Dec 5]. Available from: https://www.morphosys.com/media-investors/media-center/morphosys-ag-primary-endpoint-met-in-real-world-data-study.
65. MorphoSys AG. Primary endpoint of L-MIND, a combination study of tafasitamab (MOR208) and lenalidomide, has been met, confirming previously published activity. 2019 May 16. press release. [cited 2019 Dec 5]. Available from: https://www.morphosys.com/media-investors/media-center/morphosys-ag-primary-endpoint-of-l-mind-a-combination-study-of.
66. Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J Infect Dis. 2018;218(suppl_5):S612–S626. doi:10.1093/infdis/jiy285.
67. Regeneron Pharmaceuticals, Inc. Regeneron reports third quarter 2019 financial and operating results. 2019 Nov 5. press release. [cited 2019 Dec 5]. Available from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2019-financial-and-operating.
68. Mulangu S, Dodd LE, Davey RT, Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019 Nov 27. doi:10.1056/NEJMoa1910993.
69. Y-mabs Therapeutics, Inc. Y-mAbs initiates rolling submission of biologics license application to U.S. FDA for naxitamab for treatment of neuroblastoma. 2019 Nov 29. press release. [cited 2019 Dec 5]. Available from: http://ir.ymabs.com/node/7156/pdf..
70. Y-mabs Therapeutics, Inc. Y-mAbs announces naxitamab update. 2019 Oct 25. press release. [cited 2019 Dec 5]. Available from: http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-naxitamab-update..
71. Y-mabs Therapeutics, Inc. Y-mAbs announces second quarter 2019 financial results and recent corporate developments. 2019 Aug 14. press release. http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-second-quarter-2019-financial-results-and..
72. Eli Lilly and Company. Pfizer and Lilly announce top-line results from long-term phase 3 study of tanezumab in patients with osteoarthritis. 2019 Apr 18. press release. https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-long-term-phase-3.
73. Eli Lilly and Company. Lilly reports second-quarter 2019 financial results, raises 2019 EPS guidance. 2019 Jul 30. press release. [cited 2019 Dec 5]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2019-financial-results-raises-2019.
74. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: A randomized clinical trial. JAMA. 2019;322(1):37–48. doi:10.1001/jama.2019.8044.
75. Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, Walz T, Pepinsky RB, Bussière T, Hamann S, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018 23;8(1):6412. doi:10.1038/s41598-018-24501-0.
76. Biogen Inc., Eisai, Co., Ltd. Biogen plans regulatory filing for aducanumab in Alzheimer’s disease based on new analysis of larger dataset from phase 3 studies. 2019 Oct 22. press release. [cited 2019 Dec 5]. Available from: http://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease.
77. Regeneron Pharmaceuticals, Inc. Regeneron announces positive topline results from phase 3 trial of evinacumab in patients with severe, inherited form of high cholesterol. 2019 Aug 14. press release. [cited 2019 Dec 5]. Available from: https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-topline-results-phase-3-trial.
78. Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, et al. Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease. Front Pharmacol. 2019;10:39. doi:10.3389/fphar.2019.00039.
79. Roche. Pipeline summary as of July 25, 2019 (slides 5, 72, 73). [cited 2019 Dec 5]. Available from: https://www.roche.com/dam/jcr:9fb4878c-e3a2-4fdc-80f6-62d435df7367/en/pharmahy19.pdf.
80. Peyrin-Biroulet L, Feagan BG, Mansfield J, Rubin DT, Arulmani U, Maciuca R, Tyrrell H, Thommes J, Tole S. Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study. European Crohn’s and Colitis Organization meeting OP011. 2017. [cited 2019 Dec 5]. Available from: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2017/item/op011-etrolizumab-treatment-leads-to-early-improvement-in-symptoms-and-inflammatory-biomarkers-in-anti-tnf-refractory-patients-in-the-open-label-induction-cohort-of-the-phase-3-hickory-study.html.
81. Bioveractiv Inc. Bioverativ announces first patient dosed in phase 3 study of BIVV009 for treatment of cold agglutinin disease. 2018 Mar 6. press release. [cited 2019 Dec 5]. Available from: https://www.sanofigenzyme.com/en/about-us/newsroom/Bioverativ/2018/2018-03-06-07-30-00.
82. Sanofi. Sanofi delivered solid growth in Q2 2019. 2019 Jul 29. press release. [cited 2019 Dec 5]. Available from: https://www.sanofi.com/en/media-room/press-releases/2019/2019-07-29-07-30-00.
83. Sanofi. Pivotal data from phase 3 study of sutimlimab in cold agglutinin disease to be presented at ASH 2019 late-breaking session. 2019 Nov 21. press release. [cited 2019 Dec 5]. Available from: https://www.sanofigenzyme.com/en/about-us/newsroom/2019/2019-11-21-09-22-00.
84. AstraZeneca PLC. Year-to-date and Q3 2019 results. 2019 Oct 24. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_announcement.pdf.
85. AstraZeneca PLC. Anifrolumab phase III trial meets primary endpoint in systemic lupus erythematosus. 2019 Aug 29. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html.
86. AstraZeneca PLC. Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in phase III TULIP 2 trial. 2019 Nov 11. press release. [cited 2019 Dec 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial.html.
87. Provention Bio, Inc. Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European medicines agency. Oct 24, 2019 press release. [cited 2019 Dec 5]. Available from: http://investors.proventionbio.com/2019-10-24-Provention-Bio-Announces-PRV-031-Teplizumab-Granted-PRIME-Designation-by-the-European-Medicines-Agency.
88. Provention Bio, Inc. Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing. 2019 Sept 24. press release. [cited 2019 Dec 5]. Available from: http://investors.proventionbio.com/2019-09-24-Provention-Bio-Reiterates-Regulatory-Strategy-for-PRV-031-and-Announces-Completion-of-Follow-on-Financing.
89. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, et al.; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–13. doi:10.1056/NEJMoa1902226.
90. GlaxoSmithKline plc. Third quarter 2019. 2019 Oct 30. press release. [cited 2019 Dec 5]. Available from: https://www.gsk.com/media/5735/q3-2019-results-announcement.pdf.
91. Sesen Bio. Sesen bio reports third quarter 2019 financial results and update on regulatory activities related to vicinium. 2019 Nov 12. press release. [cited 2019 Dec 5]. Available from: https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-reports-third-quarter-2019-financial-results-and.
92. Dickstein R, Wu N, Cowan B, Dunshee C, Franks M, Wolk F, Belkoff L, Castellucci S, Holzbeierlein J, Kulkarni G, et al. VISTA, phase 3 trial of Vicinium, an EPCAM-targeted Pseudomonas exotoxin, in BCG-unresponsive non-muscle invasive bladder cancer. Global Congress on Bladder Cancer 2018; 2018 Sep 20–21; Madrid, Spain. [cited 2019 Dec 5]. Available from: https://sesenbio.com/wp-content/uploads/2019/01/BLADDR_Congress_2018_Posterl.pdf.
93. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069.
94. MacroGenics provides update on corporate progress and second quarter 2019 financial results. 2019 Jul 31. press release. [cited 2019 Dec 5]. Available from: http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-and-second-3.
95. Rugo HS, Im S-A, Wright GLS, Escriva-de-Romani S, DeLaurentiis M, Cortes J, Wazeen Bahadur S, Haley BB, Oyola RH, Riseberg DA, et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). American Society of Clinical Oncology annual meeting; 2019 June 4; [cited 2019 Dec 5]. Available from: https://meetinglibrary.asco.org/record/170929/abstract.
96. GlaxoSmithKline. Second quarter 2019 results. 2019 Jul 24. press release. [cited 2019 Dec 5]. Available from: https://www.gsk.com/media/5663/q2-2019-results-announcement.pdf.
97. GlaxoSmithKline. Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer. 2019 Mar 19. press release. [cited 2019 Dec 5]. Available from: https://us.gsk.com/en-us/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/.
98. Novartis. Q3 2019 results. investor presentation. 2019 Oct 22. p.20. [cited 2019 Dec 5]. Available from: https://www.novartis.com/sites/www.novartis.com/files/q3-2019-ir-presentation.pdf
99. Long GV, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Arance Fernandez AM, Richtig E, Yamazaki N, Robert C, Schadendorf D, et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: updated efficacy and safety from parts 1 and 2 of COMBI-i. Abstract #9531. 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4; Chicago, [cited 2019 Dec 5]. Available from: IL.https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9531.
100. Y-mAbs Therapeutics, Inc. United States securities and exchange commission form 8-K. 2019 Nov 1. [cited 2019 Dec 5]. Available from: https://www.sec.gov/Archives/edgar/data/1722964/000110465919058623/a19-21369_38k.htm.
101. ADC Therapeutics SA. United States securities and exchange commission form F-1. 2019 Sept 6. [cited 2019 Dec 5]. Available from: https://www.sec.gov/Archives/edgar/data/1771910/000114036119016305/nt10002526x5_f1.htm.
102. Breous-Nystrom E, Schultze K, Meier M, Flueck L, Holzer C, Boll M, Seibert V, Schuster A, Blanusa M, Schaefer V, et al. Retrocyte Display® technology: generation and screening of a high diversity cellular antibody library. Methods. 2014;65(1):57–67. doi:10.1016/j.ymeth.2013.09.003.
103. Agenus Inc. United States securities and exchange commission form 10-Q for the quarterly period ended June 30, 2019. 2019 Aug 9. [cited 2019 Dec 5]. Available from: https://investor.agenusbio.com/SEC-Filings.
104. Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019:clincanres.1133.2019. doi:10.1158/1078-0432.CCR-19-1133.
105. AbbVie Inc. AbbVie discontinues rovalpituzumab tesirine (Rova-T) research and development program. 2019 Aug 29. press release. [cited 2019 Dec 5]. Available from: https://news.abbvie.com/news/press-releases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-research-and-development-program.htm.
106. Eli Lilly and Company. Lilly to establish an access program for patients as it prepares to withdraw Lartruvo from the global market. 2019 Apr 25. press release. [cited 2019 Dec 5]. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-establish-access-program-patients-it-prepares-withdraw.